Division of Bausch Health Companies Inc.
Latest From AB Sanitas
Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.
AXA Private Equity's acquisition of Riemser Arzneimittel is the third change of ownership in the European specialty pharmaceuticals and manufacturing sectors this month, with more likely to follow as buyout specialists seeks the right combination of companies for consolidation.
Cinven’s $730 million acquisition of the U.K.-based specialty company Mercury Pharma could act as a platform to consolidate the sector in Europe, suggests the private equity company.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Senior Management
Nerijus Drobaricius, CFO
Saulius Jurgelenas, Gen. Manager
- Contact Info
Phone: 370 37226725
Veiveriu Str. 134B
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.